January 7, 2019
Stelexis Therapeutics closes $43 million Series A financing
New York-based cancer therapeutics company, Stelexis Therapeutics has closed a $43 million Series A financing to expand its proprietary platform to discover and selectively target pre-cancerous stem cells.